BIST10014.251,29▼ 0.00%Merck's PCSK9 Pill Lipfendra Gets FDA Nod, Shaking Pharma Stocks and LDL Treatment LandscapeUSD/TRY47.3101▲ 0.20%Netflix Boosts Revenue by 13% to $12.6 Billion – Market ImplicationsEUR/TRY53.9617▲ 0.30%Emirates NBD Launches Real‑Time Blockchain Payments on Partior, Pioneering MENATBTC/USD$64,164▼ -1.30%Meta’s AI Gambit: Alexandr Wang Leads the Superintelligence RaceGOLD6.037,24▲ 0.15%Himax's HE Series iToF Decoders Redefine 3D Sensing and Robotics MarketsBRENT$84.40▼ 0.00%Arteris and IC‑Link Team Up to Accelerate AI and HPC Chip Development Lucid Group Refutes Bankruptcy Rumors While Restructuring Costs Surge to $158 MillionBIST10014.251,29▼ 0.00%Merck's PCSK9 Pill Lipfendra Gets FDA Nod, Shaking Pharma Stocks and LDL Treatment LandscapeUSD/TRY47.3101▲ 0.20%Netflix Boosts Revenue by 13% to $12.6 Billion – Market ImplicationsEUR/TRY53.9617▲ 0.30%Emirates NBD Launches Real‑Time Blockchain Payments on Partior, Pioneering MENATBTC/USD$64,164▼ -1.30%Meta’s AI Gambit: Alexandr Wang Leads the Superintelligence RaceGOLD6.037,24▲ 0.15%Himax's HE Series iToF Decoders Redefine 3D Sensing and Robotics MarketsBRENT$84.40▼ 0.00%Arteris and IC‑Link Team Up to Accelerate AI and HPC Chip Development Lucid Group Refutes Bankruptcy Rumors While Restructuring Costs Surge to $158 Million

Global MarketsJuly 16, 2026 at 05:10 PM

Healthcare ETF Showdown: iShares Global Healthcare Outperforms Invesco in 2026

724FinanceKemal Tekin

Healthcare ETF Showdown: iShares Global Healthcare Outperforms Invesco in 2026

The iShares Global Healthcare (IXJ) and Invesco S&P 500 Equal Weight Health Care (RSPH) ETFs are facing a performance gap in 2026. While IXJ covers 110 global healthcare stocks, RSPH focuses on 60 U.S. companies. IXJ's $4.1 billion AUM offers significantly higher liquidity than RSPH's $734.1 million.

Higher Yields and Global Leadership IXJ boasts a 1.50% dividend yield, doubling RSPH's 0.70%. Top holdings for IXJ include Eli Lilly (10.6%) and Johnson & Johnson (7.1%).

Performance Edge Over Five Years IXJ grew to $1,257, outperforming RSPH's $1,177. IXJ's 18.1% max drawdown is lower than RSPH's 22%, indicating reduced risk.

As Kemal Tekin, I see IXJ's advantage in global coverage and liquidity, while RSPH's focus on U.S. stocks may limit its appeal to international investors.